We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+5.67%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.78B
AUM Growth
–
Cap. Flow
+$4.65B
Cap. Flow
% of AUM
97.21%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
616
New
605
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$91.9M |
| 2 |
CELG
Celgene Corp
CELG
|
+$79.7M |
| 3 |
Apple
AAPL
|
+$78.2M |
| 4 |
Qualcomm
QCOM
|
+$73.5M |
| 5 |
Amgen
AMGN
|
+$71.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.38% |
| 2 | Financials | 14.02% |
| 3 | Technology | 12.7% |
| 4 | Industrials | 8.01% |
| 5 | Energy | 6.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
United Therapeutics
UTHR
$26.3B
| $3.75M | 0.08% |
+29,000
| New | +$3.74M |
|
|
ACHN
277
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.74M | 0.08% |
+305,000
| New | +$3.72M |
|
|
GEVA
278
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $3.71M | 0.08% |
+40,000
| New | +$3.16M |
|
|
HES
279
DELISTED
Hess
HES
| $3.69M | 0.08% |
+50,018
| New | +$3.96M |
|
280
United Rentals
URI
$71.1B
| $3.65M | 0.08% |
+35,828
| New | +$3.84M |
|
281
Canadian National Railway
CNI
$78.3B
| $3.63M | 0.08% |
+52,532
| New | +$3.59M |
|
|
BHI
282
DELISTED
Baker Hughes
BHI
| $3.6M | 0.08% |
+64,191
| New | +$3.62M |
|
|
TWX
283
DELISTED
Time Warner Inc
TWX
| $3.52M | 0.07% |
+41,169
| New | +$3.28M |
|
284
SBA Communications
SBAC
$18.4B
| $3.44M | 0.07% |
+31,097
| New | +$3.5M |
|
285
Becton Dickinson
BDX
$43.1B
| $3.44M | 0.07% |
+25,301
| New | +$3.24M |
|
286
Insmed
INSM
$23.2B
| $3.4M | 0.07% |
+220,000
| New | +$3.12M |
|
287
TJX Companies
TJX
$170B
| $3.33M | 0.07% |
+97,068
| New | +$3.09M |
|
288
Target
TGT
$62.1B
| $3.29M | 0.07% |
+43,404
| New | +$2.93M |
|
|
AVDL
289
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.29M | 0.07% |
+192,000
| New | +$2.74M |
|
290
Canadian Natural Resources
CNQ
$96.9B
| $3.27M | 0.07% |
+218,232
| New | +$3.56M |
|
|
RGLS
291
DELISTED
Regulus Therapeutics
RGLS
| $3.21M | 0.07% |
+1,667
| New | +$2.96M |
|
292
Alnylam Pharmaceuticals
ALNY
$36.3B
| $3.2M | 0.07% |
+33,000
| New | +$3.06M |
|
293
Pacira BioSciences
PCRX
$1.02B
| $3.19M | 0.07% |
+36,000
| New | +$3.41M |
|
|
EIGR
294
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.13M | 0.07% |
+356
| New | +$2.07M |
|
295
Franklin Resources
BEN
$16.9B
| $3.1M | 0.06% |
+56,051
| New | +$3.1M |
|
296
BioCryst Pharmaceuticals
BCRX
$2.37B
| $3.08M | 0.06% |
+253,000
| New | +$2.79M |
|
297
Danaher
DHR
$135B
| $3.02M | 0.06% |
+52,381
| New | +$2.84M |
|
298
Stryker
SYK
$127B
| $3.01M | 0.06% |
+31,956
| New | +$2.83M |
|
299
Automatic Data Processing
ADP
$100B
| $3M | 0.06% |
+36,025
| New | +$2.92M |
|
|
IMMU
300
DELISTED
Immunomedics Inc
IMMU
| $3M | 0.06% |
+625,000
| New | +$2.47M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Candriam SCA, which disclosed 616 positions worth $4.78B. Its ten largest holdings account for 14% of the portfolio.
Its largest position is Gilead Sciences: 888,125 shares worth $83.7M.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, followed by Financials and Technology.
- Candriam SCA's largest Q4 2014 buy was Gilead Sciences: 888,125 shares worth $83.7M.
- Candriam SCA's ten largest holdings make up 14% of its $4.78B portfolio in Q4 2014.
- Candriam SCA disclosed 616 positions in Q4 2014, its first 13F filing on record.
Based on Candriam SCA's 13F filing for Q4 2014, filed 26 Mar 2015.